Notice: This company has been marked as potentially delisted and may not be actively trading. Range Cancer Therapeutics ETF Rating Add Compare Share Share Ratings Stock AnalysisHeadlinesHoldingsRatingsShort InterestTrends Range Cancer Therapeutics ETF Aggregate Rating and Price Target (2025)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.CNCR Aggregate RatingModerate Buy 2.78Holdings in CNCR have an aggregate rating of Moderate Buy based on 460 analyst ratings issued in the past year covering 50 companies (78.8% of the portfolio).CNCR Aggregate Price Target$12.11High Prediction$12.11Average Prediction$12.11Low Prediction$12.11Holdings in CNCR have an aggregate price target of $12.11 and a range of $12.11 to $12.11 covering 50 companies (78.8% of the portfolio).CNCR Consensus Ratings of HoldingsStrong Buy1 Strong Buy rating(s)Buy23 Buy rating(s)Moderate Buy17 Moderate Buy rating(s)Hold8 Hold rating(s)Reduce1 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by Range Cancer Therapeutics ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 50 CNCR Holdings Export to ExcelWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings3.35%RXRXRecursion Pharmaceuticals$6.88+5.4%2.2985 of 5 stars2.40$8.75 27.2%5Gap Up2.83%DNAGinkgo Bioworks$11.55+6.6%0.6746 of 5 stars1.60$4.58 -60.4%52.53%CMPXCompass Therapeutics$2.61+0.4%3.2047 of 5 stars2.67$11.80 352.1%6Short Interest ↑Gap Up2.33%VORVor Biopharma$1.36+2.3%2.1076 of 5 stars3.00$11.36 735.1%72.30%EXELExelixis$36.43+0.6%4.6945 of 5 stars2.53$35.50 -2.6%192.08%BPMCBlueprint Medicines$111.96+1.7%1.1311 of 5 stars2.65$122.72 9.6%201.95%BMYBristol-Myers Squibb$57.01+1.3%4.9175 of 5 stars2.29$56.27 -1.3%21Positive News1.93%ZYMEZymeworks$14.29+3.0%3.8696 of 5 stars2.86$19.17 34.1%7Insider TradePositive News1.92%PGENPrecigen$1.18+6.3%3.9681 of 5 stars2.60$6.33 436.7%51.77%GLUEMonte Rosa Therapeutics$5.69+0.5%3.0699 of 5 stars2.67$14.00 146.0%3Short Interest ↑Positive News1.73%SWTXSpringWorks Therapeutics$36.35+5.0%1.4906 of 5 stars3.00$70.00 92.6%61.71%REPLReplimune Group$11.85+16.9%4.2397 of 5 stars3.13$17.29 45.9%8News CoverageGap UpHigh Trading Volume1.70%ELVNEnliven Therapeutics$22.00+2.5%2.0202 of 5 stars3.20$38.25 73.9%51.69%GNLXGenelux$2.89+17.5%1.1222 of 5 stars3.20$18.25 531.5%5Gap UpHigh Trading Volume1.64%XNCRXencor$20.45+6.3%4.1191 of 5 stars3.13$34.88 70.5%81.63%SDGRSchrödinger$21.33+12.3%1.6743 of 5 stars2.82$32.90 54.2%111.58%KPTIKaryopharm Therapeutics$0.69+4.1%4.0021 of 5 stars3.00$5.00 627.9%41.58%BNTXBioNTech$117.25+4.8%1.7725 of 5 stars2.88$142.72 21.7%171.57%DAWNDay One Biopharmaceuticals$12.24-2.4%1.7881 of 5 stars3.00$35.86 193.0%91.55%RVMDRevolution Medicines$40.16-0.3%4.4712 of 5 stars3.08$66.25 65.0%121.53%MGNXMacroGenics$3.003.6685 of 5 stars2.36$7.63 154.2%111.52%IMCRImmunocore$30.00+3.4%2.5876 of 5 stars2.54$65.64 118.8%13Positive News1.51%IBRXImmunityBio$3.22+9.5%2.4116 of 5 stars3.00$13.58 321.8%41.50%ACLXArcellx$66.57+0.1%3.2561 of 5 stars3.13$105.93 59.1%15Short Interest ↑1.48%MRKMerck & Co., Inc.$96.18-1.8%4.9993 of 5 stars2.67$123.00 27.9%21Analyst ForecastNews CoveragePositive News1.44%RCUSArcus Biosciences$14.11+0.6%2.0617 of 5 stars3.00$34.00 141.0%9News Coverage1.44%KYMRKymera Therapeutics$43.70+7.6%2.729 of 5 stars2.88$55.06 26.0%17Analyst ForecastGap Up1.43%NUVBNuvation Bio$2.60+3.4%2.2285 of 5 stars3.00$7.40 185.2%51.41%JANXJanux Therapeutics$40.91+0.5%3.5227 of 5 stars3.08$89.90 119.8%131.39%HCMHUTCHMED$14.21+0.1%2.5944 of 5 stars2.00$19.00 33.7%1Gap Up1.39%TYRATyra Biosciences$15.91-1.7%2.8058 of 5 stars3.00$30.50 91.7%6Insider Trade1.38%GMABGenmab A/S$21.80+4.8%4.3855 of 5 stars2.67$45.20 107.3%9Gap Up1.37%MRUSMerus$39.74+0.7%3.3634 of 5 stars3.14$85.64 115.5%141.34%INBXInhibrx$14.19+5.2%0.9792 of 5 stars2.002News Coverage1.33%IPHAInnate Pharma$1.77+4.4%3.0813 of 5 stars3.50$11.50 551.6%2News CoveragePositive News1.33%AURAAura Biosciences$7.93+2.1%2.6931 of 5 stars3.29$23.00 190.0%7Insider TradeNews Coverage1.32%NRIXNurix Therapeutics$19.60+2.4%2.1902 of 5 stars2.94$30.35 54.9%17Analyst Forecast1.31%CRBUCaribou Biosciences$1.52-0.7%2.6618 of 5 stars3.00$10.33 579.8%51.24%APLMApollomics$9.52-0.4%2.3716 of 5 stars3.00$200.00 2,000.8%11.23%SNDXSyndax Pharmaceuticals$13.67+4.5%3.7523 of 5 stars2.90$36.20 164.8%101.21%ARVNArvinas$18.57+2.9%2.5895 of 5 stars2.93$63.50 241.9%151.18%IMRXImmuneering$2.12+5.0%3.6472 of 5 stars2.38$12.80 503.8%81.17%NUVLNuvalent$78.28+3.2%1.962 of 5 stars2.86$112.36 43.5%141.17%ACRVAcrivon Therapeutics$5.65-2.2%1.5621 of 5 stars3.00$23.67 318.9%6Short Interest ↑1.15%ALLOAllogene Therapeutics$1.84+1.1%2.5999 of 5 stars2.90$9.73 429.0%101.15%GERNGeron$2.96+2.4%3.7457 of 5 stars3.09$7.25 144.9%11Gap Up1.14%ERASErasca$1.90+2.7%2.8869 of 5 stars3.00$5.70 200.0%51.12%ZNTLZentalis Pharmaceuticals$2.25+0.4%2.8956 of 5 stars2.44$10.00 344.4%9Gap Down1.11%ITOSiTeos Therapeutics$8.06+0.8%3.8535 of 5 stars3.00$22.25 176.1%41.09%RAPTRAPT Therapeutics$1.204.2973 of 5 stars2.15$9.56 696.3%13Gap Up This page (NASDAQ:CNCR) was last updated on 1/22/2025 by MarketBeat.com Staff From Our PartnersBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump currency shock imminentTrump's Quiet $1.9 Trillion Move Against the Fed A small army of Americans, with Trump's support, has launc...Stansberry Research | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Range Cancer Therapeutics ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Range Cancer Therapeutics ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
